AIMS/HYPOTHESIS: The immune-mediated elimination of pancreatic beta cells in type 1 diabetes involves release of cytotoxic cytokines such as IL-1beta and IFNgamma, which induce beta cell death in vitro by mechanisms that are both dependent and independent of nitric oxide (NO). Nuclear factor kappa B (NFkappaB) is a critical signalling molecule in inflammation and is required for expression of the gene encoding inducible NO synthase (iNOS) and of pro-apoptotic genes. NFkappaB has recently been shown to associate with chromatin-modifying enzymes histone acetyltransferases and histone deacetylases (HDAC), and positive effects of HDAC inhibition have been obtained in several inflammatory diseases. Thus, the aim of this study was to investigate whether HDAC inhibition protects beta cells against cytokine-induced toxicity. MATERIALS AND METHODS: The beta cell line, INS-1, or intact rat islets were precultured with HDAC inhibitors suberoylanilide hydroxamic acid or trichostatin A in the absence or presence of IL-1beta and IFNgamma. Effects on insulin secretion and NO formation were measured by ELISA and Griess reagent, respectively. iNOS levels and NFkappaB activity were measured by immunoblotting and by immunoblotting combined with electrophoretic mobility shift assay, respectively. Viability was analysed by 3-(4,5-dimethyldiazol-2-yl)-2,5-diphenyl-tetrazolium bromide and apoptosis by terminal deoxynucleotidyl transferase mediated dUTP nick end labeling (TUNEL) assay and histone-DNA complex ELISA. RESULTS: HDAC inhibition reduced cytokine-mediated decrease in insulin secretion and increase in iNOS levels, NO formation and apoptosis. IL-1beta induced a bi-phasic phosphorylation of inhibitor protein kappa Balpha (IkappaBalpha) with the 2nd peak being sensitive to HDAC inhibition. No effect was seen on IkappaBalpha degradation and NFkappaB DNA binding. CONCLUSIONS/ INTERPRETATION: HDAC inhibition prevents cytokine-induced beta cell apoptosis and impaired beta cell function associated with a downregulation of NFkappaB transactivating activity.
AIMS/HYPOTHESIS: The immune-mediated elimination of pancreatic beta cells in type 1 diabetes involves release of cytotoxic cytokines such as IL-1beta and IFNgamma, which induce beta cell death in vitro by mechanisms that are both dependent and independent of nitric oxide (NO). Nuclear factor kappa B (NFkappaB) is a critical signalling molecule in inflammation and is required for expression of the gene encoding inducible NO synthase (iNOS) and of pro-apoptotic genes. NFkappaB has recently been shown to associate with chromatin-modifying enzymes histone acetyltransferases and histone deacetylases (HDAC), and positive effects of HDAC inhibition have been obtained in several inflammatory diseases. Thus, the aim of this study was to investigate whether HDAC inhibition protects beta cells against cytokine-induced toxicity. MATERIALS AND METHODS: The beta cell line, INS-1, or intact rat islets were precultured with HDAC inhibitors suberoylanilide hydroxamic acid or trichostatin A in the absence or presence of IL-1beta and IFNgamma. Effects on insulin secretion and NO formation were measured by ELISA and Griess reagent, respectively. iNOS levels and NFkappaB activity were measured by immunoblotting and by immunoblotting combined with electrophoretic mobility shift assay, respectively. Viability was analysed by 3-(4,5-dimethyldiazol-2-yl)-2,5-diphenyl-tetrazolium bromide and apoptosis by terminal deoxynucleotidyl transferase mediated dUTP nick end labeling (TUNEL) assay and histone-DNA complex ELISA. RESULTS: HDAC inhibition reduced cytokine-mediated decrease in insulin secretion and increase in iNOS levels, NO formation and apoptosis. IL-1beta induced a bi-phasic phosphorylation of inhibitor protein kappa Balpha (IkappaBalpha) with the 2nd peak being sensitive to HDAC inhibition. No effect was seen on IkappaBalpha degradation and NFkappaB DNA binding. CONCLUSIONS/ INTERPRETATION: HDAC inhibition prevents cytokine-induced beta cell apoptosis and impaired beta cell function associated with a downregulation of NFkappaB transactivating activity.
Authors: Flavio Leoni; Gianluca Fossati; Eli C Lewis; Jae-Kwon Lee; Giulia Porro; Paolo Pagani; Daniela Modena; Maria Lusia Moras; Pietro Pozzi; Leonid L Reznikov; Britta Siegmund; Giamila Fantuzzi; Charles A Dinarello; Paolo Mascagni Journal: Mol Med Date: 2005 Jan-Dec Impact factor: 6.354
Authors: Dan P Christensen; Mattias Dahllöf; Morten Lundh; Daniel N Rasmussen; Mette D Nielsen; Nils Billestrup; Lars G Grunnet; Thomas Mandrup-Poulsen Journal: Mol Med Date: 2011-01-25 Impact factor: 6.354
Authors: Danny Hung-Chieh Chou; Edward B Holson; Florence F Wagner; Alicia J Tang; Rebecca L Maglathlin; Timothy A Lewis; Stuart L Schreiber; Bridget K Wagner Journal: Chem Biol Date: 2012-06-22
Authors: M Lundh; D P Christensen; M Damgaard Nielsen; S J Richardson; M S Dahllöf; T Skovgaard; J Berthelsen; C A Dinarello; A Stevenazzi; P Mascagni; L G Grunnet; N G Morgan; T Mandrup-Poulsen Journal: Diabetologia Date: 2012-07-07 Impact factor: 10.122
Authors: Bernhard Maier; Takeshi Ogihara; Anthony P Trace; Sarah A Tersey; Reiesha D Robbins; Swarup K Chakrabarti; Craig S Nunemaker; Natalie D Stull; Catherine A Taylor; John E Thompson; Richard S Dondero; Eli C Lewis; Charles A Dinarello; Jerry L Nadler; Raghavendra G Mirmira Journal: J Clin Invest Date: 2010-05-24 Impact factor: 14.808
Authors: M Lundh; D P Christensen; D N Rasmussen; P Mascagni; C A Dinarello; N Billestrup; L G Grunnet; T Mandrup-Poulsen Journal: Diabetologia Date: 2010-09-28 Impact factor: 10.122
Authors: Ercument Dirice; Raymond W S Ng; Rachael Martinez; Jiang Hu; Florence F Wagner; Edward B Holson; Bridget K Wagner; Rohit N Kulkarni Journal: J Biol Chem Date: 2017-08-31 Impact factor: 5.157